Published in final edited form as:

Org Lett. 2008 November 20; 10(22): 5269–5271. doi:10.1021/ol802065d.

Synthesis and Anti-fungal Activity of (–)-(Z)-Dysidazirine

Colin K. Skepper[†], Doralyn S. Dalisay[†], and Tadeusz F. Molinski^{*,†,§}

[†]Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive MC0358, La Jolla, CA, 92093

[§]Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive MC0358, La Jolla, CA, 92093

Abstract

A short, flexible synthesis of the marine natural product (2*R*)-(Z)-dysidazirine (–)-1 has been completed. (–)-1 shows significant antifungal activity across a panel of seven human pathogens, while the structural analogue (–)-2, featuring a terminal *tert*-butyl group, is essentially inactive.

Invasive fungal infections, particularly those associated with *Candida* sp., pose a serious and increasing threat to human health. Widespread use of fluconazole since the mid-1990s has led to the rise of resistant *Candida* strains (e.g. *Candida glabrata* and *Candida albicans*) and attendant increased mortality among immunocompromised individuals.^{1,2} New antifungal agents are urgently needed, and marine natural products represent an underexploited source of potential leads.²

(2*R*)-(E)-Dysidazirine, (–)-3, one of a few rare naturally occurring azacyclopropenes (2*H*-azirines), was isolated in 1987 from the marine sponge *Dysidea fragilis* (collected in Fiji).³ Compound (–)-3 exhibited potent anti-fungal activity against *Candida albicans* and *Sacharomyces cerevisiae* (4 μg/disk, disk-diffusion assay). More recently, brominated analogues **4** and (+)-**6** (antazirines) were isolated along with (Z)-dysidazirine (**1**) and (2*S*)-(E)-dysidazirine [(+)-**3**] from the same sponge species collected in Micronesia.⁴ Antifungal activity for **4** and (+)-**6** were not reported,⁴ and they were found to be inactive against a panel of bacteria.

We recently isolated three new antazirine analogues ((+)-**5**, (+)-**7**, (–)-**8**) from a sample of *D. fragilis* that also provided the two known antazirines ((+)-**4** and (+)-**6**).⁵ All five antazirines proved to be inactive against a panel of *Candida* and *Cryptococcus* spp., in stark contrast with (–)-**3**. This surprising result led us to hypothesize that terminal substitution (eg. Br, Cl, Me) attenuates antifungal activity in long chain 2*H*-azirines. In order to explore this hypothesis, we have developed a short, flexible synthesis of (–)-**1** and a structural analogue (–)-**2** that features a terminal *tert*-butyl group.

There is only one published synthesis of a long chain 2*H*-azirine, that of *E*-dysidazirine, completed in 1995 by Davis and coworkers.⁶ In this case, the key azirine ring was formed by

treating an appropriately substituted *N*-(*p*-tolylsulfinyl)-2-carbomethoxyaziridine with LDA at -78°C . While this approach allowed for synthesis of (–)-**3** with high optical purity, the necessity to preserve the *Z* configuration in (–)-**1** required an alternate approach. We chose a strategy based on a variant of the asymmetric cinchona base-catalyzed Neber reaction of *O*-tosyloximes first reported by Zwanenburg and coworkers.⁷

Synthesis of (2*R*)-(Z)-dysidazirine [(–)-**1**] began with addition of the lithio-anion of pentadecyne (**9**) to methyl malonyl chloride (**10**, Table 1). The addition gave poor, variable yields when the deprotonation of **9** was effected with *n*-BuLi; using EtMgBr, however, led to clean formation of **11** in a reproducible 70% yield.

Keto-ester **11** was converted to the corresponding oxime ($\text{NH}_2\text{OH}\cdot\text{HCl}$, pyridine, EtOH, 55°C , 30 min) which was tosylated immediately (*p*-toluenesulfonic anhydride, pyridine, DMAP, 1.5 h) giving **12** in two steps (72% yield). Treatment of **12** with quinidine (0°C , 48 h) lead to clean, albeit slow, formation of the desired 2*H*-azirine ring.⁷ While the product azirine was formed with only modest enantioselectivity, this methodology is notable for its practical simplicity and high chemical yield.

Partial hydrogenation of (–)-**13** using Lindlar's catalyst at ambient temperature in EtOH proved difficult due to facile reduction of the product alkene and the azirine ring within minutes. An improvement was found by lowering the temperature of hydrogenation (0°C , hexanes) to give (Z)-dysidazirine [(–)-**1**] in 52% yield and optical purity (59% ee) comparable to the related natural products.⁵

In order to examine the effect of terminal substitution on antifungal activity, analogue (–)-**2** was synthesized starting with Wittig reaction between phosphonium bromide **14** and 3,3-dimethylbutanal, giving alkene **15** as a mixture of double bond isomers. Hydrogenation of **15** (H_2 , Pd/C, EtOAc, 1.5 h) gave saturated alcohol **16** which was oxidized under Swern conditions to give the corresponding aldehyde.⁸ Treating the crude aldehyde immediately with $\text{PPh}_3/\text{CBr}_4$ (CH_2Cl_2 , 0°C , 1 h)⁹ afforded dibromoalkene **17** which was subsequently converted to terminal alkyne **18** (*n*-BuLi, THF, $-78^{\circ}\text{C} \rightarrow \text{rt}$) in 86% overall yield from **16**. Addition of the lithiated acetylide ion of **18** to **10** proceeded reliably to give **19**, albeit in moderate yield (45%).

Keto-ester **19** was converted to the corresponding oxime-tosylate **20** (71%) which underwent quinidine-mediated cyclization to give the desired azirine (–)-**21** in 80% yield. Cyclization of **20** proceeded even more slowly than the corresponding reaction with **12**, and required brief warming to 10°C to ensure complete consumption of starting material. Lindlar reduction of (–)-**21** gave (–)-(R)-17,17-dimethyl-(Z)-dysidazirine [(–)-**2**] in 58% yield.

Both (–)-**1** and (–)-**2** were screened for antifungal activity against a panel of *Candida* and *Cryptococcus* spp. (Table 2). Synthetic (Z)-dysidazirine [(–)-**1**] showed strong activity against each fungal strain (MIC_{50} 2–8 $\mu\text{g/mL}$) with the exception of *C. krusei* (MIC_{50} 16 $\mu\text{g/mL}$). This appears to be consonant with the activity originally reported for isomeric (–)-*E*-**3** in 1988.³ In contrast, compound (–)-**2** with the bulky *tert*-butyl chain terminus was effectively inactive across the entire panel.

This surprising result points a subtle complexity in mechanism of action for (–)-**1**. The target of (–)-**1** in fungi is unknown, however it is likely to involve essential metabolism of lipids.

The electrophilic properties of the strained α,β -unsaturated azacyclopropene suggests, at first glance, that the anti-fungal activity of (–)-**1** might arise from non-specific Michael addition to nucleophilic amino acid residues (e.g. cysteine, lysine). The differential activity observed for (–)-**1** and (–)-**2** however, argues for a more specific effect that involves metering of the lipid

chain.¹⁰ We postulate that (–)-**1** engages its target protein in a two-point binding motif in which the lipid chain occupies a hydrophobic pocket with stringent steric requirements while the electrophilic α,β -unsaturated azirine carboxylate terminus binds at a distal site. The specificity of this interaction with respect to chain length remains to be investigated, however it is notable that dysidazirine shares a common chain length (C₁₈) with several sphingolipids important for fungal cell growth, such as phytosphingosine and ceramide.² This suggests dysidazirine may be an ‘antimetabolite’ that interdicts fungal cell lipid metabolism, perhaps sphingolipid biosynthesis. A more extensive study of SAR and mechanism of action of (–)-**1** is underway and our results will be reported in due course.

In summary, we have completed the first synthesis of the marine natural product (–)-(Z)-dysidazirine⁴ and a structural analogue (–)-**2** that features a terminal *tert*-butyl group. Compound (–)-**1** shows significant antifungal activity toward a range of *Candida* and *Cryptococcus* species, but (–)-**2** is almost completely inactive. This surprising result suggests that the activity of (Z)-dysidazirine is modulated by two-point binding to an as-yet unidentified target protein in fungal cells. Interaction between (–)-**1** and its putative target likely involves sterically stringent interaction between the lipid side chain and a hydrophobic domain.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We are grateful to Kathy Holten (University of Texas Medical Center) and Dr. Angie Gelli (UC Davis School of Medicine) for clinical isolates of *Candida* spp. and *Cryptococcus neoformans*, respectively. MS analysis was performed by the UCSD Chemistry/Biochemistry Mass Spectrometry Facility. We are grateful for support for this research from the NIH (AI 039987).

References

1. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snyderman DR, Wagener MM, Rinaldi MG, Yu VL. Am. J. Med 1996;100:617–623. [PubMed: 8678081]
2. a) Vicente MF, Basilio A, Cabello A, Peláez F. Clin. Microbiol. Infect 2003;9:15–32. [PubMed: 12691539] b) Bernan VS, Greenstein M, Carter GT. Curr. Med. Chem.: Anti-infective Agents 2004;3:181–195. c) Molinski TF. Curr. Med. Chem.: Anti-infective Agents 2004;3:197–220. d) Li, H-y; Matsunaga, S.; Fusetani, N. Curr. Org. Chem 1988;2:649–682.
3. Molinski TF, Ireland CM. J. Org. Chem 1988;53:2103–2105.
4. Salomon CE, Williams DH, Faulkner DJ. J. Nat. Prod 1995;58:1463–1466. [PubMed: 7494151] Neither $[\alpha]_D$ nor optical purity were reported for natural (Z)-antazirine (**4**) or (Z)-dysidazirine (**1**). See also ref. 5.
5. Skepper CK, Molinski TF. J. Org. Chem 2008;73:2592–2597. [PubMed: 18321120] All *naturally occurring* long-chain azirines from marine sponges, appear to be heterochiral (non-racemic mixtures of enantiomers).
6. a) Davis FA, Reddy GV, Liu H. J. Am. Chem. Soc 1995;117:3651–3652. b) Davis FA, Liu H, Liang C-H, Reddy GV, Zhang Y, Fang T, Titus DD. J. Org. Chem 1999;64:8929–8935. [PubMed: 11674800]
7. Verstappen MMH, Ariaans GJA, Zwanenburg B. J. Am. Chem. Soc 1996;118:8491–8492.
8. Leopold EJ. Org. Synth 1986;64:164.
9. Corey EJ, Fuchs PL. Tetrahedron Lett 1972;36:3769–3772.
10. It is unlikely the effects are due to differential cell wall permeability since the $\log_{10}P$ of (–)-**1** and (–)-**2** are similar (6.8 and 7.6, respectively, ChemDraw Ultra)

Figure 1.

Structures of (*Z*)- and (*E*)-dysidazirine [(*-*)-**1** and (*-*)-**3**], antazirines [(*+*)-**4–8**] and synthetic (*Z*)-dysidazirine analogue [(*-*)-**2**].

Scheme 1. Synthesis of (–)-(Z)-dysidazirine **1**^a % *ee* for (–)-**1** = 59% (determined by chiral HPLC: Chiralpak AD, 90:10 hexanes/*i*-PrOH).

Scheme 2.
Synthesis of 14,14-dimethylpentadecyne (**18**)

Scheme 3.

Synthesis of 17,17-dimethyl-(Z)-dysidazirine

^a % *ee* for (-)-2 = 60% (HPLC, Chiralpak AD, 10:90, *i*-PrOH /hexanes).

Table 1
Optimization of pentadecyne addition to methyl malonyl chloride

entry	base	solvent	T1 °C	time1 (min)	equiv 10	T2 °C	time2 (min)	yield (%)
1	<i>n</i> -BuLi	THF	0	90	0.5	-78 → 0	150	0 ^a
2	<i>n</i> -BuLi	Et ₂ O	-20	60	0.5	-60 → 0	120	14 ^a
3	EtMgBr	Et ₂ O	0 → rt	80	0.5	0	40	0 ^b
4	EtMgBr	THF	0 → rt	120	0.8	0	50	19
5	EtMgBr	THF	0 → rt	150	0.5	0	60	70

^a Estimated from crude NMR.

^b Compound **11a** was isolated in 35% yield.

Table 2Antifungal activity of (–)-**1** and (–)-**2**^a

	MIC ₅₀ (µg/mL)	
	(–)- 1	(–)- 2
<i>C. albicans</i> ATCC 14503	8	>64
<i>C. albicans</i> UCD-FR1 ^b	8	>64
<i>C. albicans</i> 96–489 ^b	4	>64
<i>C. glabrata</i> ^b	4	16
<i>C. krusei</i>	16	>64
<i>Cryptococcus neoformans</i> var. <i>grubii</i>	2	9
<i>Cryptococcus neoformans</i> var. <i>gatti</i>	2	>64

^aThe *in vitro* susceptibility of each compound was determined by the broth micro dilution method according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS).

^bFluconazole resistant (MIC > 64 µg/mL).